RAPT Therapeutics (NASDAQ:RAPT) Stock, Quote.Headers.trade-ideas

RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Earnings

Earnings Beats

News

Penny Stocks

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ADPT

ANIP

LSTA

RAPT

Lisata Therapeutics, Inc.&#39;s (NASDAQ: LSTA) lead pipeline candidate is certepetide (formerly known as LSTA1), which is being developed for treating a range of solid tumors.

Lisata Stock Rallies More Than 30% YTD: Here&#39;s Why

Biotech

BEAM

Beam Therapeutics Inc. (NASDAQ: BEAM) is evaluating its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease, an inherited blood disorder.

Here&#39;s Why You Should Invest in Beam Therapeutics Now

ACRV

ATHA

Athira Pharma, Inc (NASDAQ: ATHA) recently announced that it has dosed the last patient in the phase II/III LIFT-AD study, which is evaluating its pipeline candidate, fosgonimeton for the treatment of mild-to-moderate Alzheimer&#39;s disease (AD).

Athira Completes Dosing in Alzheimer&#39;s Study, Stock Up

RAPT Therapeutics Inc

Wolfe downgrades RAPT, but still sees "immense" upside potential

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

TimesSquare Capital U.S. Small/Mid Cap Growth Q1 2024 Commentary

RAPT Therapeutics to cut 40% of workforce to save cash

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on RAPT Therapeutics (RAPT – Research Report) today. The company's shares closed yes...

RAPT Therapeutics (RAPT) Gets a Hold from H.C. Wainwright

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

RAPT Therapeutics GAAP EPS of -$0.71 beats by $0.05

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>RAPT Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/rapt-stock-quote/"><strong>RAPT</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>RAPT Therapeutics reported earnings per share of -71 cents. This was above the analyst estimate for EPS of -72 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/rapt-stock-earnings-rapt-therapeutics-for-q2-of-2024/">RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024

In a report released today, Leon Wang from Barclays maintained a Hold rating on RAPT Therapeutics (RAPT – Research Report), with a price target of ...

Barclays Remains a Hold on RAPT Therapeutics (RAPT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), RAPT Ther...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), RAPT Therapeutics (RAPT) and Liquidia Technologies (LQDA)

ALNY

ASND

ATRC

BMBL

CYBR

ESAB

EXPO

FIVE

FROG

FRPT

GLBE

KRYS

LQDA

MSTR

MTDR

NICE

ONTO

SMAR

SMCI

SYNA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

Press Releases

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

RAPT Therapeutics Reports First Quarter 2024 Financial Results

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Aileron Therapeutics, Inc. - Common Stock

Aileron Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Celularity

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

CEL-SCI

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Eagle Pharmaceuticals, Inc. - Common Stock

Eagle Pharmaceuticals

Elicio Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

Gritstone Bio

Immuneering Corporation - Class A Common Stock

Immuneering

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kronos Bio

MAIA Biotechnology

Mural Oncology

OS Therapies

Ovid Therapeutics

Serina Therapeutics

Spero Therapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

Tevogen Bio Holdings

Vor Biopharma

Barclays

JP Morgan

Leerink Partners

Berenberg

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

RAPT Therapeutics

RAPT Therapeutics (RAPT) Forecast

RAPT Therapeutics (NASDAQ:RAPT) Stock, Quote.Headers.trade-ideas